The role of academia is an essential one for digital health. In addition to providing the platform to conduct clinical research and showcase where technology can create impact, the right environment also becomes the training ground for future leaders and change makers. In this episode, I speak with Dean Ho, who is one of the unique individuals who effectively bridges the different worlds of academia and business building. Dean is the Provost’s Chair Professor, Director of The N.1 Institute for Health (N.1), Director of the Institute for Digital Medicine (WisDM), and Head of the Department of Biomedical Engineering at the National University of Singapore. He's also an experienced business builder and entrepreneur. In our conversation we cover: • The evolving role of academia in becoming a hands-on partner for Health Innovation • The impact of Digital Health including AI on regulatory • How National University of Singapore is taking a role in designing the next generation of clinical innovation • The need for Digital Therapeutics in APAC Professor Dean Ho Using his CURATE.AI platform, Prof.Dean Ho has led multiple pioneering clinical studies that have validated the promise of N-of-1 medicine, where only a patient’s own data is used to personalise their treatment for the entire duration of care. Multiple CURATE.AI-based clinical studies are ongoing or cleared for start in the areas of solid cancer and blood cancer therapy, digital therapeutics/personalised learning, and post-organ transplant immunosuppression, among others.  Prof. Ho is an elected member of the US National Academy of Inventors (NAI). He is also a Fellow of the American Institute of Medical and Biological Engineering (AIMBE), the Royal Society of Chemistry, and Society for Laboratory Automation and Screening, as well as a Fulbright Scholar. Prof Ho is also currently a Subgroup Lead of the World Health Organization-ITU AI for Health Working Group for Regulatory Considerations. He has also served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a 26,000+ member global drug development organization comprised of senior executives from the pharmaceutical and medical device sectors, as well as academic thought leaders.  Prof. Ho is a recipient of the Tech Heroes from Crisis: Pathfinder Award from the Singapore Computer Society, NSF CAREER Award, Wallace H. Coulter Foundation Translational Research Award, and V Foundation for Cancer Research Scholar Award, among others. Prof. Ho was also named to the Asia Tatler Gen.T List, which honours young leaders who are shaping the future of the region. Prof. Ho has appeared on the National Geographic Channel Program “Known Universe” to discuss his discoveries in drug delivery and imaging. His discoveries have been featured on CNN, The Economist, Forbes, Washington Post, NPR and other international news outlets. He has advised major publicly listed companies as well as venture capital and private equity funds in the areas of digital medicine and pharmaceutical development, among other sectors. Guest's Links and Resources Connect with Dean Ho: LinkedIn | Twitter The N.1 Institute for Health (N.1): Website | Twitter | LinkedIn WisDM: Twitter Host's Links and Resources: Connect with Tony Estrella: Twitter | LinkedIn | Personal Website Connect with Taliossa Read Tony’s Book: Comatose FutureProofing Healthcare | FutureProofing Healthcare APAC index Full White Paper, Summary and Video: A Vision for Asia Pacific in 2050 Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Special thanks to: Bayer G4A Takeda Roche